- Home
- SVRN vs KLRS Comparison
SVRN vs KLRS Comparison
Compare SVRN & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRN | KLRS |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 46.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SVRN | KLRS |
|---|---|---|
| Price | $0.40 | $10.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | ★ 217.7K | 54.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $2.14 |
| 52 Week High | $1.47 | $11.90 |
Technical Indicators
Market Signals| Indicator | SVRN | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 15.90 | 55.24 |
| Support Level | N/A | $8.08 |
| Resistance Level | $1.35 | $10.36 |
| Average True Range (ATR) | 0.05 | 1.11 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 11.04 | 71.61 |
Price Performance
Historical ComparisonAbout SVRN OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.